Arcutis Completes Enrollment In Infant Atopic Dermatitis Trial Of ZORYVE Cream; Data Due In Q1, 2026

Core Insights - Arcutis Biotherapeutics, Inc. has completed enrollment in its INTEGUMENT-INFANT Phase 2 trial for ZORYVE cream 0.05% targeting infants with mild to moderate atopic dermatitis [1][3] Company Overview - ZORYVE is a topical PDE4 inhibitor and is recognized as the leading branded therapy for atopic dermatitis, seborrheic dermatitis, and plaque psoriasis [3] - The cream works by blocking PDE4, which reduces pro-inflammatory mediators, thereby calming skin inflammation and restoring immune balance [3] Clinical Trial Details - The INTEGUMENT-INFANT study is an open-label, multicenter Phase 2 trial assessing the safety and tolerability of ZORYVE cream 0.05% over a four-week period involving 101 infants [3] - Topline data from this study is anticipated to be available in Q1 2026 [3] Market Context - Atopic dermatitis affects nearly 9.6 million children in the U.S., with up to 60% showing symptoms within their first year of life [2] - ZORYVE cream 0.05% was approved in October 2025 for children aged 2 to 5 years, providing a steroid-free alternative to corticosteroids for mild to moderate atopic dermatitis [4] Stock Performance - ARQT's stock has fluctuated between $8.90 and $27.08 over the past year, closing at $22.86, down 2.52%, but rebounding to $23.51 in overnight trading, up 2.84% [5]